Dr. Thiel, Partner at Sanemus AG, gave a lecture at the University of Maastricht, Management School, on May 8th, 2017. In his lecture, his main topic was the question: “Which sort of qualification is needed to succesfully establish a start-up?”
If you want to know more about the presentation of Dr. Michael Thiel and if you want to find out how to really achieve succes with a start-up, please do not hesitate to contact us.
Supporting a diagnostics start-up in finding new investors
SANEMUS is supporting a diagnostics start-up focused on the identification and characterization of circulating tumor cells (CTC) in finding new investors. The start-up has developed a patent-protected innovative diagnostic system, which is able to identify all CTCs with higher sensitivity and specificity and faster throughput compared to current systems on the market. The address of first VCs has occured, talks with interested parties are on-going to close the Series A in Q1/Q2 2018. If you are interested in participating, please contact us.
Supporting a biotech start-up in attracting venture capital
The SANEMUS team supervises a biotech start-up in attracting venture capital, which has developed a proprietary technology platform for the encapsulation of nucleid acids (siRNA, mRNA) as well as low molecular compounds. The goal is the development of new RNA drugs in cancer therapy and the therapy of genetic defects. Talks are currently taking place with institutional VCs. The goal ist the closing of Series A round in Q1/Q2 2018. If you are interested in participating, please contact us.
German family office invests in European Life Science VC fund
A German family office in the field of plant manufacturing has again invested tens of millions in an European Life Science VC fund on the recommendation of SANEMUS AG. At that time, SANEMUS prepared an overview of the healthcare market with its investment opportunities for the family office, which was the basis for the investment decision of the family office. If you are interested in participating in a Life Science VC fund, please contact us.
SCOPE Symposium Maastrich 2017
Dr. Thiel, Partner at Sanemus AG, gave a lecture at the University of Maastricht, Management School, on May 8th, 2017. In his lecture, his main topic was the question: “Which sort of qualification is needed to succesfully establish a start-up?”
If you want to know more about the presentation of Dr. Michael Thiel and if you want to find out how to really achieve succes with a start-up, please do not hesitate to contact us.
Life Sciences Venture Capital-funds on the rise
In his article “Life Sciences Venture Capital-funds on the rise” in the april issue of VentureCapital magazine, Dr. Thiel reports about the success of European Life Sciences Venture Capital funds in 2016. Many large funds, such as the Endeavour Vision III-fund and Life Science Partners V-fund raised more than 200 mio. euros. Particulary pleasing from a German point of view was the first closing of the Earlybird HealthTech fund, as the public German health insurer Barmer GEK is represented here as an investor for the first time.
You can read the whole article here→ (German-language link)
SANEMUS wins European VC investors for Exact Imaging
Exact Imaging Inc. (Toronto), a Canadian Medtech Start-Up, successfully closed its Series C Financing Round on December 22nd 2016 at the amount of CAD 21.5 Mio. (15.4 Mio. €). SANEMUS AG was in charge of finding the European investors.
Please find more information in the press release
The SANEMUS team supports a second Canadian Start-Up for raising venture capital
The SANEMUS team supports a second Canadian medtech Start-Up for raising venture capital. The Start-Up has developed a non-invasive device to prevent reperfusion injuries caused by ischemia. The team is currently actively searching co-investors in Europe.
SANEMUS supports a Canadian medtech Start-Up for the fundraising
Our team supports a Canadian medtech Start-Up for the fundraising. The Start-Up has developed a high-resolution ultrasound technology for the identification of tumor tissue during a prostate biopsy. An European lead-investor could be identified. The team is currently in the process of putting the investors syndicate together.
SANEMUS elaborates concept for strategic redirection of a German pharmaceutical company
The SANEMUS team supports a German mid-sized pharmaceutical company for its strategic redirection. The focus lies on the elaboration of strategic options for an expansion of its business to ensure a sustainable growth in the future. Portfolio optimization, in and out licensing of products as well as the optimal marketing and sales support of the new portfolio are the main issues of the strategic redirection.
SANEMUS elaborates a relaunch strategy for mid-sized German pharma company
Our team supports a mid-sized German pharmaceutical company for the elaboration of a relaunch strategy for an oncology drug. The main focus is on preparing a commercially attractive business case for the relaunch. Moreover the implementation of the future marketing and sales strategy will be supervised.